X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (692) 692
Newsletter (68) 68
Publication (52) 52
Newspaper Article (32) 32
Book Review (14) 14
Book Chapter (12) 12
Magazine Article (5) 5
Transcript (4) 4
Dissertation (3) 3
Conference Proceeding (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
axitinib (780) 780
index medicus (387) 387
humans (343) 343
oncology (328) 328
sorafenib (277) 277
sunitinib (236) 236
cancer (228) 228
carcinoma, renal cell (197) 197
male (177) 177
renal cell carcinoma (176) 176
carcinoma, renal cell - drug therapy (174) 174
female (164) 164
kidney neoplasms - drug therapy (161) 161
metastasis (160) 160
middle aged (154) 154
care and treatment (142) 142
vascular endothelial growth factor (141) 141
aged (126) 126
drug therapy (115) 115
pazopanib (112) 112
research (108) 108
everolimus (107) 107
pharmacology & pharmacy (103) 103
kidney cancer (101) 101
antineoplastic agents - therapeutic use (99) 99
treatment outcome (99) 99
adult (97) 97
survival (94) 94
efficacy (92) 92
interferon-alpha (92) 92
imidazoles - therapeutic use (91) 91
indazoles - therapeutic use (90) 90
kidney neoplasms - pathology (90) 90
analysis (89) 89
protein kinase inhibitors - therapeutic use (88) 88
bevacizumab (86) 86
disease-free survival (84) 84
targeted therapy (82) 82
immunotherapy (77) 77
medicine & public health (75) 75
angiogenesis (70) 70
carcinoma, renal cell - pathology (70) 70
tyrosine kinase inhibitor (70) 70
trial (69) 69
pharmaceutical industry (67) 67
phase-ii (65) 65
animals (63) 63
clinical trials (63) 63
therapy (63) 63
renal-cell carcinoma (62) 62
double-blind (61) 61
antineoplastic agents - adverse effects (60) 60
dosage and administration (59) 59
metastatic renal cell carcinoma (59) 59
safety (58) 58
tumors (58) 58
tyrosine (58) 58
imidazoles - adverse effects (57) 57
indazoles - adverse effects (57) 57
endothelial growth-factor (56) 56
health aspects (56) 56
imidazoles - administration & dosage (56) 56
indazoles - administration & dosage (56) 56
urology & nephrology (55) 55
patients (53) 53
protein kinase inhibitors - adverse effects (53) 53
chemotherapy (52) 52
indazoles - pharmacology (52) 52
imidazoles - pharmacology (51) 51
aged, 80 and over (50) 50
cancer therapies (50) 50
receptors, vascular endothelial growth factor - antagonists & inhibitors (50) 50
tyrosine kinase inhibitors (50) 50
carcinoma (48) 48
inhibitor (48) 48
hypertension (47) 47
niacinamide - analogs & derivatives (47) 47
carcinoma, renal cell - secondary (44) 44
open-label (44) 44
retrospective studies (44) 44
angiogenesis inhibitors - therapeutic use (43) 43
prognosis (43) 43
solid tumors (43) 43
development and progression (42) 42
ag-013736 (41) 41
patient outcomes (41) 41
protein kinase inhibitors - pharmacology (41) 41
antimitotic agents (40) 40
antineoplastic agents (40) 40
clear cell-type renal cell carcinoma (40) 40
medical research (40) 40
protein kinase inhibitors - administration & dosage (39) 39
vegf (39) 39
cabozantinib (38) 38
phase-iii trial (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
medical prognosis (36) 36
metastases (36) 36
pharmacokinetics (36) 36
pharmacology/toxicology (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (763) 763
German (18) 18
Russian (10) 10
French (8) 8
Japanese (5) 5
Czech (3) 3
Polish (3) 3
Spanish (3) 3
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Sanidad militar: revista de sanidad de las Fuerzas Armadas de España, ISSN 1887-8571, 2012, Volume 68, Issue 3, pp. 177 - 181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3639 - 3644
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to... 
GROWTH-FACTOR | AXITINIB | ONCOLOGY | CARCINOMA
Journal Article
The Oncologist, ISSN 1083-7159, 02/2019, Volume 24, Issue 2, pp. 143 - 145
This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma,... 
AXITINIB | ONCOLOGY | COMBINATION | CANCER
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 405 - 415
Journal Article
by Liu, XS and Wang, BL and Chen, C and Qi, ZP and Zou, FM and Wang, JJ and Hu, C and Wang, AL and Ge, J and Liu, QW and Yu, KL and Hu, ZQ and Jiang, ZR and Wang, W and Wang, L and Wang, WC and Ren, T and Bai, MF and Liu, QS and Liu, J
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2019, Volume 62, Issue 10, pp. 5006 - 5024
Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as... 
CELLS | CHEMISTRY, MEDICINAL | AXITINIB | EFFICACY | SAFETY | IMATINIB | RESISTANCE | SUNITINIB | MECHANISMS
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. 725 - 727
Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell... 
EVEROLIMUS | AXITINIB | ONCOLOGY | BEVACIZUMAB | SUNITINIB | COMBINATION | NIVOLUMAB | CANCER | Commentaries
Journal Article
International Journal of Molecular Sciences, ISSN 1422-0067, 09/2019, Volume 20, Issue 19, p. 4712
This paper reviews current treatments for renal cell carcinoma/cancer (RCC) with the multikinase inhibitors (MKIs) sorafenib, sunitinib, lenvatinib and... 
sunitinib | renal cell carcinoma | sorafenib | lenvatinib | multikinase inhibitor | hypertension | axitinib
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was... 
renal cell carcinoma | hyperkalemia | adverse event | axitinib
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 08/2018, Volume 29, Issue 7, pp. 705 - 709
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1030 - 1037
Purpose: We hypothesized that axitinib is active with an improved safety profile in nasopharyngeal carcinoma (NPC). Experimental Design: We evaluated axitinib... 
TRIAL | CANCER-PATIENTS | THERAPY | SOLID TUMORS | ONCOLOGY | RECURRENT | RADIOTHERAPY | PATIENTS PTS | COMBINATION | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Axitinib - administration & dosage | Pain - epidemiology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Axitinib - pharmacokinetics | Diarrhea - epidemiology | Male | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Pain - chemically induced | Weight Loss - drug effects | Diarrhea - chemically induced | Nasopharyngeal Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Young Adult | Antineoplastic Agents - adverse effects | Nasopharyngeal Neoplasms - blood | Hypertension - chemically induced | Inhibitory Concentration 50 | Adult | Female | Antineoplastic Agents - pharmacokinetics | Hypertension - epidemiology | Nasopharyngeal Neoplasms - drug therapy | Axitinib - adverse effects | Nasopharyngeal Carcinoma - blood | Neoplasm Recurrence, Local - blood | Thyrotropin - blood | Drug Administration Schedule | Hemorrhage - epidemiology | Disease Progression | Xenograft Model Antitumor Assays | Animals | Fatigue - epidemiology | Nasopharyngeal Carcinoma - pathology | Cell Line, Tumor | Nasopharyngeal Carcinoma - drug therapy | Aged | Mice | Hemorrhage - chemically induced | Hypertension | Slopes | Toxicity | Diarrhea | Fatigue | Pharmacology | Hypothyroidism | Disease control | Patients | Hemorrhage | Metastases | Nasopharyngeal carcinoma | Thyroid-stimulating hormone | Chemotherapy | Pain | Experimental design | Platinum | Correlation analysis | Safety engineering | Blood pressure | Safety | Pharmacokinetics | Cancer | Thyroid
Journal Article
ONCOLOGIST, ISSN 1083-7159, 02/2015, Volume 20, Issue 2, pp. 196 - 201
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3. Based on the positive opinion from... 
ONCOLOGY | Renal cell carcinoma | EMA | Axitinib | Inlyta | European Medicines Agency
Journal Article
Value in Health, ISSN 1098-3015, 12/2018, Volume 21, Issue 12, pp. 1413 - 1418
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 06/2019, Volume 380, Issue 26, pp. 2582 - 2582
To the Editor: Henderson et al. (March 21 issue)(1) provide a detailed analysis of a 58-year-old woman with severe vitamin D deficiency related to vitamin... 
MEDICINE, GENERAL & INTERNAL | Kidney Neoplasms | Axitinib | Carcinoma, Renal Cell | Sunitinib | Antibodies, Monoclonal | Humans
Journal Article
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 04/2018, Volume 22, Issue 4, pp. 2153 - 2161
Aberrant receptor kinase signalling and tumour neovascularization are hallmarks of medulloblastoma development and are both considered valuable therapeutic... 
multi-kinase inhibitor | MEDICINE, RESEARCH & EXPERIMENTAL | targeted therapy | medulloblastoma | SAFETY | PLUS AXITINIB | PI3K inhibitor | PHASE-II | SORAFENIB | COMBINATION | GDC-0941 | RENAL-CELL CARCINOMA | CELL BIOLOGY | TYROSINE KINASE INHIBITORS | THERAPY | GROWTH ARREST | VIVO EFFICACY | Axitinib
Journal Article
Journal Article
Urologia Internationalis, ISSN 0042-1138, 06/2019, Volume 102, Issue 4, pp. 435 - 440
Background: The side effects of sunitinib, namely onset of hypertension and hypothyroidism, have been reported to be predictive biomarkers of treatment... 
Original Paper | Metastatic renal cell carcinoma | Hypothyroidism | Axitinib
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.